Inhibition of Skp2-cyclin a interaction
View Patent ↗Methods of killing a cancer cell are provided. Also provided are methods of treating a subject having a cancer. Additionally, compounds are provided that comprise a peptide from about 18 to about 100 amino acids or peptidomimetics comprising the sequence of SEQ ID NO:1. Additionally provided are methods of screening an agent for the ability to kill a cancer cell.
1. A method of screening an agent for the ability to kill a cancer cell, the method comprising determining whether the agent inhibits Skp2-cyclin A binding by (a) combining the agent with a cyclin A and a compound comprising the sequence of SEQ ID NO:1 and which comprises from 18 to about 100 amino acids or peptidomimetics under conditions which permit the compound to bind to the cyclin A in the absence of the agent, and (b) determining whether the compound binds to the cyclin A in the presence of the agent, wherein an agent inhibits Skp2-cyclin A binding if the agent causes a reduction in binding of the compound to the cyclin A and
wherein an agent that inhibits Skp2-cyclin A binding could kill the cancer cell.
2. The method of claim 1 , wherein an agent that inhibits Skp2-cyclin A binding is further tested for its ability to kill the cancer cell.
3. The method of claim 1 , wherein the agent is an organic compound less than 1000 daltons.
4. The method of claim 1 , wherein the peptide comprises the sequence of SEQ ID NO:3.
5. The method of claim 1 , wherein the peptide consists of the sequence of SEQ ID NO:3.
6. The method of claim 1 , wherein the compound is labeled with a detectible moiety.